Table 1.
Published remission and relapse rates
| Remission
| ||||||
|---|---|---|---|---|---|---|
| Ref | Design | Intervention (n) | Follow up, years (range) | Retention | Remission rates | Predictors |
| (9) | Prospective | RYGB (298) | Up to 14 | 96% | 91% | Younger age, shorter T2DM duration |
| (11) | Prospective | RYGB (191) | Mean 1.64 (0.5–4.8) | 80% | 83% | Shorter T2DM duration, no insulin use |
| (4) | RCT | AGB (30) | 2 | 92% | AGB: 73% | Weight loss, prior A1C |
| MT (30) | MT: 13% | |||||
| (13) | Prospective | RYGB (22) | (2-3) | 56% | RYGB: 72% | Not analyzed |
| AGB (12) | AGB: 17% | |||||
| (12) | RCT | RYGB (60) | 1 | 95% | RYGB: 75% | Weight loss |
| MT (60) | MT: 32% | |||||
| (14) | Prospective | BS (343) | Median 10 | 29% | BS: 30.4% | Shorter T2DM duration |
| MT (343) | MT: 6.5% | |||||
|
| ||||||
| Remission and relapse
| ||||||
| Remission/Relapse rates | Predictors of relapse | |||||
|
| ||||||
| (35) | Retrospective | RYGB (42) | Mean 5, at least 3 | NA | 64%/26% | Lower preop BMI, less EWL, weight regain |
| (8) | Retrospective | RYGB (177) | Mean 8.6 (5-16) | NA | 88.7%/48% | Older age, female, insulin use |
| (34) | Retrospective | RYGB (4434) | Mean 3.1 (0.1–12.75) | 67.8% | 68.2%/35% | insulin use, long T2DM duration, A1C >6.5% |
| (2,6) | RCT | RYGB (48); | 3 | 91% | RYGB: 42%/24%; | Not analyzed |
| SG (49); | SG: 37%/50%; | |||||
| MT (40) | MT: 12%/80% | |||||
| (5,36) | RCT | RYGB (19); | 5 | 88% | RYGB: 75%/63%; | None identified |
| BPD (19); | BPD: 95%/37%; | |||||
| MT (19) | MT: 0%/NA | |||||
A1C, glycated hemoglobin; AGB, adjustable gastric banding; BS, bariatric surgery; BMI, body mass index; BPD, biliopancreatic diversion; EWL, excess weight loss; MT, medical treatment; RCT, randomized control trial; RYGB, Roux-en-Y gastric bypass; SG, sleeve gastrectomy; T2DM, type 2 diabetes mellitus.